Spironolactone in resistant essential hypertension
Copyright © 2019 Elsevier Masson SAS. All rights reserved..
Resistant hypertension is defined as uncontrolled blood pressure (BP) despite three antihypertensive agents including a diuretic (thiazide diuretic if renal function is normal or loop diuretic in case of chronic kidney disease with eGFR<30mL/min), a renin-angiotensin system blocker (ARB or ACEI) and a calcium channel blocker, at optimal doses. Resistance must be confirmed by out-of-office measurements (ambulatory blood pressure monitoring or home blood pressure monitoring) and patients should be asked about treatment compliance and excessive salt or alcohol intake. If the diagnosis of resistant hypertension is confirmed, the patient should be referred to a hypertension specialist to screen for secondary causes of hypertension as they are frequent in this context. If essential resistant hypertension is confirmed, the mineralocorticoid receptor antagonist, spironolactone, should be added (25 to 50mg daily). In the event of a contraindication to spironolactone, or if adverse effects occur, a beta-blocker, an alpha-blocker, or a centrally acting antihypertensive drug should be prescribed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
|---|---|
| Enthalten in: |
Presse medicale (Paris, France : 1983) - 48(2019), 12 vom: 20. Dez., Seite 1431-1438 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
HTA essentielle résistante : place de la spironolactone |
|---|
| Beteiligte Personen: |
Lorthioir, Aurélien [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
27O7W4T232 |
|---|
| Anmerkungen: |
Date Completed 25.12.2019 Date Revised 25.12.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.lpm.2019.07.027 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM300823185 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM300823185 | ||
| 003 | DE-627 | ||
| 005 | 20231225103340.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.lpm.2019.07.027 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1002.xml |
| 035 | |a (DE-627)NLM300823185 | ||
| 035 | |a (NLM)31473027 | ||
| 035 | |a (PII)S0755-4982(19)30339-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Lorthioir, Aurélien |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Spironolactone in resistant essential hypertension |
| 246 | 3 | 3 | |a HTA essentielle résistante : place de la spironolactone |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.12.2019 | ||
| 500 | |a Date Revised 25.12.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a Resistant hypertension is defined as uncontrolled blood pressure (BP) despite three antihypertensive agents including a diuretic (thiazide diuretic if renal function is normal or loop diuretic in case of chronic kidney disease with eGFR<30mL/min), a renin-angiotensin system blocker (ARB or ACEI) and a calcium channel blocker, at optimal doses. Resistance must be confirmed by out-of-office measurements (ambulatory blood pressure monitoring or home blood pressure monitoring) and patients should be asked about treatment compliance and excessive salt or alcohol intake. If the diagnosis of resistant hypertension is confirmed, the patient should be referred to a hypertension specialist to screen for secondary causes of hypertension as they are frequent in this context. If essential resistant hypertension is confirmed, the mineralocorticoid receptor antagonist, spironolactone, should be added (25 to 50mg daily). In the event of a contraindication to spironolactone, or if adverse effects occur, a beta-blocker, an alpha-blocker, or a centrally acting antihypertensive drug should be prescribed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antihypertensive Agents |2 NLM | |
| 650 | 7 | |a Spironolactone |2 NLM | |
| 650 | 7 | |a 27O7W4T232 |2 NLM | |
| 700 | 1 | |a Belmihoub, Inès |e verfasserin |4 aut | |
| 700 | 1 | |a Fouassier, David |e verfasserin |4 aut | |
| 700 | 1 | |a Azizi, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Amar, Laurence |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Presse medicale (Paris, France : 1983) |d 1986 |g 48(2019), 12 vom: 20. Dez., Seite 1431-1438 |w (DE-627)NLM012618160 |x 2213-0276 |7 nnns |
| 773 | 1 | 8 | |g volume:48 |g year:2019 |g number:12 |g day:20 |g month:12 |g pages:1431-1438 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.lpm.2019.07.027 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 48 |j 2019 |e 12 |b 20 |c 12 |h 1431-1438 | ||